Literature DB >> 16776449

Denaturing HPLC for high-throughput screening of rifampicin-resistant Mycobacterium tuberculosis isolates.

C W Yip1, K L Leung, D Wong, D T L Cheung, M Y Chu, H S Tang, K M Kam.   

Abstract

OBJECTIVE: To evaluate the use of denaturation high-performance liquid chromatography (dHPLC) as a rapid method to detect rifampicin (RMP) resistance based on mutations in the rpoB gene in a high-volume laboratory setting.
METHODS: A total of 132 RMP-resistant Mycobacterium tuberculosis strains with different rpoB mutation were used to optimise the running condition of dHPLC as a pilot study. A blind correlation study was subsequently done between dHPLC and in vitro RMP susceptibility tests on 3167 M. tuberculosis strains in a high-throughput clinical setting.
RESULTS: In the pilot study, rpoB mutation could be detected on 116/132 (87.9%) RMP-resistant strains by dHPLC. In the second phase of the study, 84/3107 (2.7%) clinical M. tuberculosis isolates were RMP-resistant. The sensitivity and specificity of dHPLC in the prediction of RMP resistance were 70/84 (83.3%) and 70/77 (91.0%), respectively. The specificity became 100% when 511 Leu to Pro mutation was excluded from the RMP resistance-related genetic changes.
CONCLUSION: In the detection of RMP resistance in a high-throughput laboratory setting, dHPLC has been demonstrated to be rapid, simple, workable, automatable and inexpensive in terms of running costs and the labour involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16776449

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

2.  Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results.

Authors:  A Van Deun; L Barrera; I Bastian; L Fattorini; H Hoffmann; K M Kam; L Rigouts; S Rüsch-Gerdes; A Wright
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

3.  Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients.

Authors:  Ji Young Kang; Jung Hur; Shinyoung Kim; Sanghoon Jeon; Jaeha Lee; Youn Jeong Kim; Seok Chan Kim; Yeon Joon Park; Young Kyoon Kim; Hwa Sik Moon
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

4.  Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation.

Authors:  Oksana Ocheretina; Lishuang Shen; Vincent E Escuyer; Marie-Marcelle Mabou; Gertrude Royal-Mardi; Sean E Collins; Jean W Pape; Daniel W Fitzgerald
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

5.  Multi drug resistant tuberculosis in Mosango, a rural area in the Democratic Republic of Congo.

Authors:  Michel Kayomo Kaswa; Serge Bisuta; Georges Kabuya; Octavie Lunguya; André Ndongosieme; Jean Jacques Muyembe; Armand Van Deun; Marleen Boelaert
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.